Difference between revisions of "Linsitinib (OSI-906)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8})" to "[https://clinicaltrials.gov/ct2/show/$1 Clinical Trial Registry]") |
||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Gastrointestinal stromal tumor]]=== | ===[[Gastrointestinal stromal tumor]]=== | ||
| − | #'''SARC 022:''' Von Mehren M, George S, Heinrich M, Schuetze S, Yap J, Yu J, Abbott A, Litwin S, Crowley J, Belinsky M, Janeway K, Hornick J, Flieder D, Chugh R, Rink L, Van den Abbeele A; Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. Clin Cancer Res. 2020 April; 15;26(8):1837-1845. Epub 2019 Dec 2. [https://clincancerres.aacrjournals.org/content/26/8/1837.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7856429/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31792037/ PubMed] NCT01560260 | + | #'''SARC 022:''' Von Mehren M, George S, Heinrich M, Schuetze S, Yap J, Yu J, Abbott A, Litwin S, Crowley J, Belinsky M, Janeway K, Hornick J, Flieder D, Chugh R, Rink L, Van den Abbeele A; Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. Clin Cancer Res. 2020 April; 15;26(8):1837-1845. Epub 2019 Dec 2. [https://clincancerres.aacrjournals.org/content/26/8/1837.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7856429/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31792037/ PubMed] [https://clinicaltrials.gov/ct2/show/NCT01560260 Clinical Trial Registry] |
==Also known as== | ==Also known as== | ||
Revision as of 15:14, 31 May 2023
Mechanism of action
An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Linsitinib selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.
Preliminary data
Gastrointestinal stromal tumor
- SARC 022: Von Mehren M, George S, Heinrich M, Schuetze S, Yap J, Yu J, Abbott A, Litwin S, Crowley J, Belinsky M, Janeway K, Hornick J, Flieder D, Chugh R, Rink L, Van den Abbeele A; Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. Clin Cancer Res. 2020 April; 15;26(8):1837-1845. Epub 2019 Dec 2. link to original article link to PMC article contains dosing details in manuscript PubMed Clinical Trial Registry
Also known as
- Code name: OSI-906